Clinical Significance of SDC2 in Gastric Cancer: Insights From a Multi-Center Cohort Study

Gastric Cancer (GC) poses a significant global health challenge, necessitating effective biomarkers for early detection and prognosis. This study investigates the relationship between SDC2 expression and GC patient outcomes.

We analyzed SDC2 expression in GC and its association with patient outcomes using Kaplan-Meier survival and Cox regression analyses. A pan-cancer analysis was performed to assess cross-tumor SDC2 expression patterns. Validation included immunohistochemistry and single-cell data analyses to confirm SDC2 expression in GC tissues and cell types, with findings supported by independent cohort studies.

Elevated SDC2 expression correlates with poor prognosis in GC patients, marked by lower survival rates, enhanced tumor microenvironment heterogeneity, decreased tumor mutational burden, and reduced immunotherapy efficacy. Kaplan-Meier and Cox regression analyses confirm that higher SDC2 expression is associated with shorter overall survival, establishing it as an independent prognostic risk factor. Pan-cancer analysis reveals consistent SDC2 expression patterns across multiple cancers, indicating broad clinical relevance. Validation through immunohistochemistry and single-cell data analysis confirms SDC2 expression in GC tissues and cell types. Independent cohort studies further support these findings.

In summary, this study underscores the potential of SDC2 as a promising target for early diagnosis and therapeutic intervention in GC, with implications for other malignancies.